Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Financial Results:
Granules India Ltd reported Revenues for Q2FY25 of ₹967.00 Crores down from ₹1,189.00 Crore year on year, a fall of 18.67%.
Total Expenses for Q2FY25 of ₹842.00 Crores down from ₹1,056.00 Crores year on year, a fall of 20.27%.
Consolidated Net Profit of ₹97.00 Crores down 4.9% from ₹102.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹4.01, down 4.75% from ₹4.21 in the same quarter of the previous year.